Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Ettlinger

Rheumatology Tacoma, WA Medical Doctor

NPI 1740383744 CMS profile 33337

1901 South Cedar Street, 201 Cedar Medical Center, Tacoma, WA 98405

Open in the dashboard

General payments

$231,757

362 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Ettlinger of Tacoma, WA is reported in the CMS Open Payments database as having received $231,757 across 362 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34 1
2024 General $10,958 22
2023 General $13,398 29
2022 General $23,820 39
2021 General $35,465 47
2020 General $23,170 40
2019 General $124,912 184

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Ettlinger
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Robert Ettlinger were reported at $34. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Robert Ettlinger Rheumatology median Middle half National median
2019 $124,912 $744 $153–$2,687 $163
2020 $23,170 $462 $98–$2,027 $114
2021 $35,465 $531 $101–$2,153 $132
2022 $23,820 $627 $125–$2,303 $149
2023 $13,398 $741 $145–$2,524 $160
2024 $10,958 $830 $166–$2,660 $164
2025 $34 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $68,257 99 payments
  2. Celgene Corporation $35,871 43 payments
  3. Pfizer Inc. $34,871 47 payments
  4. Aurinia Pharma U.S., Inc. $25,725 40 payments
  5. Regeneron Healthcare Solutions, Inc. $21,585 41 payments
  6. Genzyme Corporation $21,217 31 payments
  7. GlaxoSmithKline, LLC. $15,315 23 payments
  8. Lilly USA, LLC $6,231 11 payments
  9. Janssen Biotech, Inc. $1,958 4 payments
  10. E.R. Squibb & Sons, L.L.C. $283 9 payments
  11. Other $444 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $184,740 92 payments
  2. Travel and Lodging $24,404 115 payments
  3. Consulting Fee $14,713 4 payments
  4. Food and Beverage $7,704 148 payments
  5. Education $196 3 payments
Products named General payments · program years 2019–2025
  1. Otezla Dermatology $35,871 43 payments
  2. XELJANZ $34,798 44 payments
  3. Enbrel Inflammation $31,404 49 payments
  4. LUPKYNIS $25,725 40 payments
  5. KEVZARA Inflammation And Immunology $21,546 41 payments
  6. Otezla Inflammation $17,575 27 payments
  7. BENLYSTA $15,315 23 payments
  8. KEVZARA Rheumatology $14,336 23 payments
  9. Enbrel Inflammation $6,591 8 payments
  10. OLUMIANT $5,268 4 payments
  11. Other $13,205 48 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

362 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record